Drug Topics
JULY 26, 2023
The Equitable Community Access to Pharmacy Services legislation was introduced earlier this year in the House of Representatives.
Pharmacy Times
JULY 26, 2023
Phenotype-based interventions are individualized treatment plans that consider genetic and phenotypic characteristics instead of general restricted eating or exercise management.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JULY 26, 2023
Ycanth (cantharidin) was approved for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older as an in-office administered therapy.
Pharmacy Times
JULY 26, 2023
Investigators said that warfarin could be considered for individuals with venous thromboembolism who have contraindications to direct oral anticoagulants and those with poor persistence on low-molecular weight heparin.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JULY 26, 2023
Investigators theorize that the inflamed skin of AD patients or treatments they are undergoing could contribute to an elevated mutation rate.
Pharmacy Times
JULY 26, 2023
Experts analyze the process by which the Advisory Committee on Immunization Practices formulates vaccine recommendations and updates them, and the implications and effects of these decisions.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JULY 26, 2023
Prothrombin complex concentrate human-Ians can quickly improve blood coagulation in patients who are at risk of excess bleeding but need urgent surgery.
Fierce Healthcare
JULY 26, 2023
Most Medicare Advantage (MA) enrollees use one or more supplemental benefits, with most health plan members using multiple benefits, according to a newly released report from the Elevance Health Pu | Extra benefits from Medicare Advantage plans are highly utilized by enrollees, which improves health outcomes among at-risk populations, new analysis shows.
Pharmacy Times
JULY 26, 2023
Product verification allows technicians to practice at the top of their license and frees pharmacists to interact with patients.
Fierce Pharma
JULY 26, 2023
As with Novo Nordisk’s popular offering for obesity, Wegovy, demand for Eli Lilly’s dual GIP/GLP-1 agonist Mounjaro appears to be outpacing supply once again. | The U.S. Food and Drug Administration has added a fourth dose of Lilly’s popular new diabetes med to its drug shortage database. The agency also expects supply issues with three other doses to persist longer than previously thought.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
JULY 26, 2023
The data could inform how non–steroidal anti-inflammatory drug-mediated mitochondrial uncoupling could affect other diseases.
STAT
JULY 26, 2023
For 15 years, orthopedic surgeon Charles S. Day has been working to highlight the striking lack of diversity in his field, publishing studies showing orthopedics had the fewest Black, Hispanic, and female residents of any surgical specialty. Day himself is Asian American, a group that’s abundant in medicine. But as he dug further, his datasets and personal experiences began to collide.
Pharmacy Times
JULY 26, 2023
The low risk of cardiovascular events was observed in all relevant subgroups, including in both males and females with HIV.
STAT
JULY 26, 2023
Nikki Saltzburg was born three months premature while her parents were vacationing in Bermuda. With Saltzburg weighing just 2 pounds, 2 ounces, they flew her back to Philadelphia on a Navy plane, the whole aircraft set to 98.8 degrees Fahrenheit so that she’d survive the journey. Saltzburg is now a 45-year-old staff psychologist at Florida Atlantic University who has been paralyzed from the waist down almost her whole life.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JULY 26, 2023
With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farxiga in this use and continue growing its r | After recent label expansions in the U.S. and Europe paid off with a sizable sales increase for Jardiance, the drug has added a third use to its European label.
STAT
JULY 26, 2023
The new director of the Centers for Disease Control and Prevention, Mandy Cohen, is only two weeks into her new job. But already she hears the clock ticking. If all goes well, Cohen — the successor to Rochelle Walensky, who stepped down at the end of June — will have about 18 months at the helm of the world’s premier public health agency before the next U.S. president is sworn in.
Fierce Pharma
JULY 26, 2023
Despite a positive opinion from local drug reviewers, GSK has decided not to bring its FDA-approved oral anemia drug daprodustat to Europe—or any additional countries for that matter. | Despite a positive opinion from local drug reviewers, GSK has decided not to bring its FDA-approved oral anemia drug daprodustat to Europe—or any additional countries for that matter.
STAT
JULY 26, 2023
One of the largest compound pharmacy operations in the U.S. recently recalled a slew of injectable medicines used by hospitals over concerns about possible side effects and a newly released regulatory report underscores the extent of the problem. The Food and Drug Administration found several issues that raised the possibility of contamination during an inspection of an Allentown, Pa., facility run by Central Admixture Pharmacy Services.
Fierce Healthcare
JULY 26, 2023
The need for speed underpins a collaborative effort by Blue Shield of California and Microsoft that will utilize the cloud to deliver data about members to the insurer and providers in real-time, t | Blue Shield of California is collaborating with Microsoft to move to its cloud platform to improve data collection, storage and analysis.
STAT
JULY 26, 2023
The country’s largest private psychiatric hospital operator cherry-picks patients whose insurance will pay more, its finance chief said on an earnings call Wednesday. It’s no secret that such hospitals, especially when run by for-profit companies, base admission decisions on how much they’ll get paid, but it’s rare to hear the practice described so bluntly.
Fierce Healthcare
JULY 26, 2023
Digital mental health company Headspace secured $105 million in new debt financing as it eyes opportunities to expand its business with employers and health plans. | Headspace CEO Russell Glass spoke with Fierce Healthcare an exclusive interview about the new debt financing, the company's recent restructuring and layoffs and future plans for the mental health company.
STAT
JULY 26, 2023
WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to clamp down on drug middlemen, but kicked the can down the road on some of the more challenging policies. The bill would offer some more transparency into the business practices of pharmacy benefit managers, ensure PBMs aren’t skimming off of the money they send to insurers, prohibit them from overcharging insurers, and ensure certain fees in the Medicare program aren’t tied to a d
Fierce Healthcare
JULY 26, 2023
In a largely harmonious Senate Committee on Finance markup hearing, members supported bipartisan efforts to rein in pharmacy benefit managers (PBMs) that they say operate without transparency to dr | The Senate wants to improve transparency surrounding pharmacy benefit managers and bring down prescription drug prices for the average person.
STAT
JULY 26, 2023
Last week, Marc Tessier-Lavigne announced that he will resign as president of Stanford over work performed many years ago, in labs at three different institutions. While most of the attention has been focused on the fall from grace of this distinguished scientist, this sad situation carries broader lessons about avoidable outcomes. A delicately worded sentence in the investigative panel’s report notes that there “may have been” opportunities to “improve laboratory ove
Fierce Healthcare
JULY 26, 2023
One in three counties in the U.S. is considered a maternal healthcare desert. | In response to the maternal mortality crisis, providers are using every seed in their seed bag by leveraging multimodal technology strategies to predict health emergencies before they happen.
STAT
JULY 26, 2023
WASHINGTON — Lawmakers in Congress generally agree that there’s something very broken with the way America pays for prescription drugs. They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices.
Fierce Pharma
JULY 26, 2023
Alkermes brought in $617 million during the second quarter, including $248 million of back royalties on Johnson & Johnson's Invega franchise. The company recently won an arbitration case against the pharma giant.
STAT
JULY 26, 2023
After months of deliberation, the European Commission has agreed to accelerate the phasing out of animal testing, but stopped short of a complete ban — a move that drawing praise from university and industry groups but outrage from animal rights activists. The decision was made in response to a citizen’s initiative , which sought to strengthen an existing ban on animal testing in cosmetics that has been in effect for about a decade.
Drug Topics
JULY 26, 2023
A recent study found that the largest positive associations were seen in former smokers and patients of Hispanic race.
Pharma Marketing Network
JULY 26, 2023
The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled. One of the FDA’s enforcement mechanisms is the issuance of marketing violation letters to pharmaceutical companies found in violation of advertising and promotion regulations.
Fierce Healthcare
JULY 26, 2023
Nevada insurance officials yesterday announced | Nevada had been the last state to give up on the idea that Friday Health Plans could somehow function until the end of the year. But now it plans to liquidate the insurtech in September.
Fierce Pharma
JULY 26, 2023
More than 2.4 million people in the United States use warfarin to keep their blood from clotting after a heart attack, stroke or other serious thromboembolic complication. | The FDA signed off on Octapharma's blood coagulant Balfaxar as a treatment to counter the effects of commonly used blood thinner warfarin.
PharmExec
JULY 26, 2023
As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
STAT
JULY 26, 2023
Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions. Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release.
Expert insights. Personalized for you.
187 
Let's personalize your content